Molecular biomedicine
Cure8 research brief
Why This Matters
The study identifies thymosin β4 as a protective factor in experimental colitis and suggests an injectable/oral recombinant peptide might reduce inflammation and intestinal fibrosis by suppressing mineralocorticoid receptor signaling—an idea that could lead to new drug development for IBD.
Who Should Pay Attention
Researchers, translational scientists, drug developers, and clinicians interested in IBD biology, fibrosis, and novel therapeutic targets.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports preclinical research showing that thymosin β4 (TMSB4X) is reduced in colonic tissue from people with IBD and that loss of the gene in mice increases susceptibility to DSS colitis.
Giving recombinant human thymosin β4 (rhTβ4) by mouth improved survival, reduced weight loss and epithelial injury, lowered inflammatory cytokines, and reduced markers of intestinal fibrosis in mouse models.
The authors link rhTβ4’s effects to suppression of mineralocorticoid receptor (MR/NR3C2) signaling using transcriptomics, reporter assays, and downstream gene analyses, and propose restoring Tβ4 activity as a potential therapeutic strategy for IBD.
This is preclinical laboratory work (mouse models, molecular assays, and transcriptomics) published as a journal article abstract. It describes candidate-target engagement and disease-modifying effects in animals and supports further research, not clinical use.
Keep In Mind
Preclinical mouse-model work and molecular assays; not a clinical trial. Findings need replication and human testing before any change in care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMolecular biomedicine
AuthorsTao-Ran Zhao, En-Bo Hu, Meng-Wei Wang +8 more
InstitutionDepartment of Biochemistry and Molecular Biology, College of Basic Medical Sciences; Shanxi Key Laboratory of Birth Defect and Cell Regeneration; MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Academy of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 17, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Ethics approval and consent to participate: All experimental procedures were approved by the Animal Laboratory of Laboratory Animal Center, Academy of Military Medical Sciences (IACUC-DWZX-2023–031), and conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
This preclinical study identifies Thymosin β4 as a protective factor in intestinal inflammation and fibrosis and suggests rhTβ4 could be explored as a new therapeutic approach for IBD by targeting mineralocorticoid...
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
The work identifies an endogenous peptide (Tβ4) that is reduced in IBD and shows that replacing it in mice lessens colitis and intestinal fibrosis, pointing to a new potential treatment target for inflammation and...
Therapeutic Efficacy of a Novel Oral NRF2 Activator in a Murine Ulcerative Colitis Model 2256177
The study presents a new oral NRF2 activator that reduced inflammation and tissue injury in a mouse model of ulcerative colitis, suggesting a potential novel therapeutic approach.